New York, USA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- DelveInsight’s report provides comprehensive global coverage of pipeline obesity therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the obesity pipeline domain. Request a sample and discover the recent advances in obesity treatment drugs @ The obesity pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage obesity drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the obesity clinical trial landscape.
Obesity involves the excessive or abnormal accumulation of fat in the body, negatively impacting health and increasing the risk of diabetes mellitus, cardiovascular disease, hypertension, and hyperlipidemia. It has become a significant public health issue, worsening over the past 50 years. Obesity is a complex condition with multiple causes, including genetic, cultural, and societal factors, and is the second leading cause of preventable death after smoking.
Achieving a 5% to 10% weight loss can greatly enhance health, quality of life, and reduce economic burdens for individuals and countries. The imbalance between daily energy intake and expenditure leads to excessive weight gain, with reduced physical activity, poor diet, insomnia, endocrine disorders, and certain medications contributing to obesity. Genetic studies have highlighted the heritability of obesity, identifying numerous genes associated with increased fat and weight.
Obesity is defined as having a body mass index (BMI) over 30, while a BMI over 25 is considered overweight. Diagnosis involves assessing BMI and measuring waist size to evaluate visceral fat, along with considering related health issues like high blood pressure, cholesterol levels, and diabetes. It is the second most common preventable cause of death, linked to cardiovascular disease, diabetes mellitus, respiratory problems, psychological issues, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia.
Obesity rates have increased in children and adults of both genders in both developed and developing countries over the past 50 years. Treating obesity usually requires a combination of lifestyle changes, medication, and sometimes weight-loss procedures. Lifestyle changes include adopting a healthy, reduced-calorie diet, increasing physical activity, and obtaining psychological support if needed.
Medications like orlistat may be recommended when lifestyle changes are insufficient. In severe cases, weight-loss surgeries or procedures such as endoscopic sleeve gastroplasty and intragastric balloon insertion can be considered. Collaborating with healthcare professionals to set realistic weight-loss goals and maintain long-term changes is crucial for improving health and reducing obesity-related complications.
Find out more about obesity treatment drugs @ Learn more about the emerging obesity pipeline therapies @ The report proffers an integral view of the obesity emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Dive deep into rich insights for new drugs for obesity treatment, visit @ For further information on the obesity pipeline therapeutics, reach out @ report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the obesity epidemiology trends. report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key obesity companies, including , among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key hypothalamic obesity companies, including , among others. report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key hypothalamic obesity companies, including , among others. report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key HET obesity/POMC deficiency obesity companies, including , among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
